India's Pharma 5.0: The Risk of Falling Behind in Drug Discovery

Capital – both finance and talent – is the third vector. Drug discovery is like portfolio finance. You underwrite uncertainty. Indian pharma firms must raise R&D spending from 8% to 12%. That means partnerships with venture capital, philanthropy, private equity, and the government. It also means bringing back the scientific diaspora and hiring experienced global talent.

Collaboration is the fourth. Discovery is a team sport. No single company does chemistry, biology, clinical development, regulation, data science, manufacturing, and commercialization equally well. The sector must work with policymakers, universities, startups, global firms, and even Japan and China.

Procurement is the fifth. Innovation policy should aim to create early markets, not just fund labs. Stanford was called the Cold War University because public funding for defence research came with clear government purchase prospects. Indian innovators need predictable public procurement, reimbursement, and inclusion in treatment guidelines.

For investors tracking Indian pharma stocks, this is a key risk to watch. See our stock market analysis for more on sector trends. Companies that raise R&D intensity and build global research centres could capture the upside. Those that stay in generics may see margins compress as competition intensifies.

The authors close with a line that sums up the stakes: "India cannot ask scientists to pursue discoveries and then make it impossible to adopt these for healthcare." The next decade will test whether the sector can move from making medicines to imagining them.